natgillin/translations-raw huggingface dataset:
ILD may occur acutely during therapy; the risk is increased in patients who had a history of ILD when treated with leflunomide.
ILD se lahko akutno pojavi med zdravljenjem; tveganje je povečano pri bolnikih, ki so med zdravljenjem z leflunomidom imeli ILD v anamnezi.
ILD or ILD-like adverse reactions were reported in 11/411 (2.7%) of patients who received TAGRISSO in the two Phase II studies, of which 0.7% were Grade 3 or 4 and 1% were fatal.
O IBP ali neželenih učinkih, podobnih IBP, so poročali pri 11/411 (2,7 %) bolnikov, ki so prejemali zdravilo TAGRISSO v dveh študijah II. faze; 0,7 % jih je bilo 3. ali 4. stopnje in 1 % je bil smrten.
ILD/Pneumonitis
IBP/pnevmonitis
ildenafil (used to treat pulmonary arterial hypertension – a lung disease that makes breathing difficult) orally administered midazolam, triazolam (used to help you sleep and/or relieve anxiety)
ildenafil (uporablja se za zdravljenje pljučne arterijske hipertenzije – bolezni pljuč, ki otežuje dihanje) peroralno uporabljen midazolam, triazolam (uporabljata se kot pomoč pri spanju in/ali za lajšanje tesnobe)
ildenafil (when used for the treatment of pulmonary arterial hypertension) ticagrelor
ildenafil (če je uporabljen za zdravljenje pljučne arterijske hipertenzije) ticagrelor
ildenafil (when used to treat pulmonary arterial hypertension – a lung disease that makes breathing difficult) orally administered midazolam, triazolam (used to help you sleep and/or relieve anxiety)
ildenafil (ko se uporablja za zdravljenje pljučne arterijske hipertenzije – bolezni pljuč, ki otežuje dihanje) peroralno uporabljen midazolam, triazolam (uporabljata se kot pomoč pri spanju in/ali za lajšanje tesnobe)
ildenafil and vardenafil, medicines used to treat impotence, and tadalafil, a medicine used to treat impotence and pulmonary hypertension
ildenafil in vardenafil; zdravili, ki se uporabljata za zdravljenje impotence, in tadalafil, zdravilo, ki se uporablja za zdravljenje impotence in pljučne hipertenzije
ildenafil for the treatment of
Kombinacija avanafila in zdravila
ildenafil if used to treat pulmonary arterial hypertension, (a condition affecting the blood vessels to your lungs) paritaprevir (used to treat hepatitis C virus infection)
ildenafil, če se uporablja za zdravljenje pljučne arterijske hipertenzije, (bolezni, ki prizadene pljučne žile) paritaprevir (uporabljamo ga za zdravljenje okužbe z virusom hepatitisa C)
ildenafil or tadalafil
ildenafil ali tadalafil
ildenafil or tadalafil
tadalafilom pri kronični
ildenafil – to treat erectile dysfunction
ildenafil – za zdravljenje motnje erekcije
ildenafil, a medicine used to treat erectile dysfunction or lung hypertension. medicines that increase the amount of potassium in the blood.
ildenafila, zdravila, ki ga uporabljamo za zdravljenje erektilne disfunkcije ali pljučne hipertenzije.
ildenafil, used to treat pulmonary arterial hypertension – a lung disease that makes breathing difficult orally administered midazolam, triazolam, used to help you sleep and/or relieve anxiety
ildenafil; uporablja se za zdravljenje pljučne arterijske hipertenzije – bolezni pljuč, ki otežuje dihanje peroralno uporabljeni midazolam, triazolam; uporabljata se kot pomoč pri spanju in/ali za lajšanje tesnobe
ildenafil, vardenafil or tadalafil (used to treat erectile dysfunction)
ildenafil, vardenafil ali tadalafil (uporabljamo jih za zdravljenje erektilne disfunkcije)
ildenafil, vardenafil, tadalafil (medicines to treat erectile dysfunction and/or pulmonary arterial hypertension) clopidogrel (a medicine to prevent blood clots).
ildenafil, vardenafil, tadalafil (zdravila za zdravljenje motenj erekcije in/ali pljučne arterijske hipertenzije) klopidogrel (zdravilo za preprečevanje nastanka krvnih strdkov)
ildenafil, vardenafil, tadalafil - used for impotence
ildenafil, vardenafil, tadalafil - za impotenco
Ileus/intestinal obstruction*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)*
ileus/zapora črevesja*, gastrointestinalna perforacija*, divertikulitis*, žilne ektazije antruma želodca (GAVE)
Ileus/intestinal obstruction*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)*
ileus/zapora črevesja*, gastrointestinalna perforacija*, iterature tis*, žilne ektazije antruma želodca (GAVE)
ilicone oil, dimethicone.
ilikonsko olje dimetikon
illness
pruritus ekhimoza
Illness and injuries
Bolezni in poškodbe
illness*, Fatigue
bolezen, podobna gripi*, utrujenost
illness, fatigue,
bolezen, utrujenost,
illness, Rigors,
gripi, rigor, zvišana
Illnesses that affect the brain, such as bipolar I disorder, may be due to certain chemicals in the brain, such as dopamine and serotonin, being out of balance and these imbalances may cause some of the symptoms you may be experiencing.
Bolezni, ki prizadenejo možgane in med katere sodi tudi bipolarna motnja I, lahko nastanejo zaradi neravnovesja določenih kemičnih snovi v možganih, kot sta dopamin in serotonin, in to lahko vodi do pojava nekaterih simptomov, ki jih imate morda tudi vi.
Illumination with appropriate red light produces reactive oxygen-containing molecules which act against the target cells.
Osvetlitev s primerno rdečo svetlobo proizvaja reaktivne molekule kisika, ki delujejo proti ciljnim celicam.
Illumination: Immediately after cleaning the lesions, the entire treatment area will be illuminated with a red light source.
Osvetlitev: takoj po čiščenju lezij se celotno območje zdravljenja osvetli z virom rdeče svetlobe.
Iloprost elimination is reduced in patients with hepatic dysfunction (see section 5.2).
Pri bolnikih z okvaro jeter je izločanje iloprosta zmanjšano (glejte poglavje 5.2).
Iloprost may increase the effects of vasodilatators and antihypertensive agents and then favour the risk of hypotension (see section 4.4).
Iloprost lahko poveča učinek vazodilatatorjev in antihipertenzivov in tako poveča tveganje za pojav hipotenzije (glejte poglavje 4.4).
ILP should be undertaken in specialised centres by surgical teams experienced in the management of limb sarcomas and ILP procedure, with an intensive care unit readily available and with the facilities for continuous monitoring for medicinal product leakage into the systemic circulation.
Zdravljenje smejo izvajati samo kirurške ekipe, ki imajo izkušnje z zdravljenjem sarkoma na okončinah in s postopkom izolirane perfuzije okončin, in sicer v specializiranih centrih z oddelkom za takojšnje intenzivno zdravljenje in opremo za neprekinjeno spremljanje uhajanja zdravila v sistemski obtok.
IM (cattle) SC (sheep)
i.m. (govedo) s.c. (ovce)
IM injection
i.m.
IM injection
IM injekcija
IM injection.
i.m. injekcija
IM olanzapine has not been studied in patients with alcohol or drug intoxication (see section 4.4).
i.m. olanzapina niso preučevali pri bolnikih z intoksikacijo z alkoholom ali drogami (glejte poglavje 4.4).
IM olanzapine should not be administered to patients with unstable medical conditions, such as acute myocardial infarction, unstable angina pectoris, severe hypotension and/or bradycardia, sick sinus syndrome, or following heart surgery.
Nestabilna zdravstvena stanja i.m. olanzapina ne smemo dajati bolnikom z nestabilnimi zdravstvenimi stanji, kot so npr. akutni miokardni infarkt, nestabilna angina pektoris, huda hipotenzija in/ali bradikardija, sindrom bolezni sinusnega vozla ali po operaciji na srcu.
IM or SC use
i.m. ali s.c. uporaba
IM use
i.m. uporaba
IM use.
i.m. uporaba
IMAGE 4 IMAGE 5
SLIKA 4 SLIKA 5
Image acquisition
Pridobivanje slike
Image acquisition
Slikanje
Image acquisition in analogue and/or digital word-mode and at least a 128 x 128 matrix is recommended.
Priporočljivo je snemanje slike v analognem in/ali digitalnem modusu in z matriko najmanj 128 x 128.
Image acquisition/sentinel lymph node mapping
Zajem slike/mapiranje varovalnih bezgavk
Image agreement
Ujemanje posnetkov
Image interpretation errors in the estimation of brain β-amyloid neuritic plaque density, including false negatives and false positives, have been observed.
Pri interpretaciji posnetkov v oceni možganske gostote β- amiloidnih nevritičnih leh so opazili napake, ki so vključevale lažno negativne in lažno pozitivne rezultate.
Images should be acquired using a gamma camera fitted with a high-resolution collimator and calibrated using the
Slike morajo biti posnete z gama kamero, na kateri je nameščen kolimator visoke ločljivosti in ki je umerjena s 159 keV.
Imaging for tissue elasticity, e.g.
slikanje za preverjanje elastičnosti tkiva, npr.
Imatinib (n=252)
imatinib (n = 252)
Imatinib 400 mg once daily (n = 283) By 6 years
imatinib 400 mg 1x/dan (n = 283) po 6 letih
Imatinib Accord 100 mg film-coated tablets are brownish orange, round biconvex, film-coated tablets, debossed on one side with ‘IM’ and ‘T1’ on either side of breakline and plain on the other side.
Imatinib Accord 100 mg filmsko obložene tablete so rjavooranžne, okrogle, bikonveksne filmsko obložene tablete z vtisnjenima oznakama “IM” in “T1” na vsaki strani zareze na eni strani tablete in brez oznake na drugi strani
Imatinib Accord 100 mg film-coated tablets Imatinib
Imatinib Accord 100 mg filmsko obložene tablete imatinib
Imatinib Accord 100 mg film-coated tablets:
Imatinib Accord 100 mg filmsko obložene tablete:
Imatinib Accord 100mg film-coated tablets Imatinib Accord 400mg film-coated tablets Imatinib
Imatinib Accord 100 mg filmsko obložene tablete Imatinib Accord 400 mg filmsko obložene tablete imatinib
Imatinib Accord 400 mg film-coated tablets are brownish orange, oval shaped, biconvex, film-coated tablets, debossed on one side with ‘IM’ and ‘T2’ on either side of breakline and plain on the other side.
Imatinib Accord 400 mg filmsko obložene tablete so rjavooranžne, ovalne, bikonveksne filmsko obložene tablete z vtisnjenima oznakama “IM” in “T2” na vsaki strani zareze na eni strani tablete in brez oznake na drugi strani.
Imatinib Accord 400 mg film-coated tablets Imatinib
Imatinib Accord 400 mg filmsko obložene tablete imatinib
Imatinib Accord 400 mg film-coated tablets:
Imatinib Accord 400 mg filmsko obložene tablete
Imatinib Accord is a treatment for adults for:
Zdravilo Imatinib Accord je tudi zdravilo za odrasle:
Imatinib Accord is a treatment for:
Zdravilo Imatinib Accord je zdravilo za odrasle in otroke s:
Imatinib Accord is a ‘generic medicine’.
Zdravilo Imatinib Accord je „generično zdravilo“.
Imatinib Accord is also a treatment for children with CML.
Zdravilo Imatinib Accord je namenjeno tudi zdravljenju otrok s KML.
Imatinib Accord is an anticancer medicine that contains the active substance imatinib.
Imatinib Accord je zdravilo proti raku, ki vsebuje zdravilno učinkovino imatinib.
Imatinib Accord is available as tablets (100 and 400 mg).
Zdravilo Imatinib Accord je na voljo v obliki tablet (100 in 400 mg).
Imatinib Accord is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut.
Zdravilo Imatinib Accord se zaužije peroralno z obrokom hrane in velikim kozarcem vode, da se tako zmanjša tveganje za draženje želodca in črevesja.
Imatinib Accord is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adults patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Zdravilo Imatinib Accord je indicirano za zdravljenje pediatričnih bolnikov z na novo diagnosticirano kronično mieloično levkemijo (KML), s prisotnim kromosomom Philadelphia (bcr-abl) (Ph+), pri katerih presaditev kostnega mozga kot zdravljenje prve izbire ne pride v poštev; pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi; odraslih bolnikov s Ph+ KML v blastni krizi; odraslih bolnikov z na novo diagnosticirano akutno limfoblastno levkemijo, s prisotnim kromosomom Philadelphia (Ph+ ALL) skupaj s kemoterapijo; odraslih bolnikov z relapsom ali neodzivno Ph+ ALL v monoterapiji; odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR – platelet derived growth factor receptor); odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFR ali z obojim; odraslih bolnikov z neresektabilnim protuberantnim dermatofibrosarkomom (DFSP - dermatofibrosarcoma protuberans) in tistih odraslih bolnikov z rekurentnim in/ali metastatskim DFSP, ki niso primerni za operacijo.
Imatinib Accord is used in children who have been newly diagnosed with Ph+ CML and who are not eligible for a bone marrow transplant.
Zdravilo Imatinib Accord se uporablja pri otrocih z na novo ugotovljeno kronično mieloidno levkemijo s kromosomom Philadelphia, pri katerih presaditve kostnega mozga ni možno izvesti.
Imatinib Accord is used in combination with other anticancer medicines in adults who have been newly diagnosed with Ph+ ALL.
Zdravilo Imatinib Accord se uporablja v kombinaciji z drugimi zdravili proti raku pri odraslih, pri katerih je bila na novo ugotovljena Ph+ ALL.
Imatinib Accord is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body.
Zdravilo Imatinib Accord se uporablja za zdravljenje odraslih z DFSP, ki ga ni mogoče kirurško odstraniti, in odraslih, ki niso primerni za operacijo, če se je rak po zdravljenju ponovil ali razširil v druge dele telesa.
Imatinib Accord is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα; dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Zdravilo Imatinib Accord se uporablja za zdravljenje odraslih s HES ali KEL, ki imajo specifično prerazporeditev dveh genov, imenovanih FIP1L1 in PDGFRα; protuberantnega dermatofibrosarkoma (DFSP), tj. vrste raka (sarkoma), pri katerem se celice v tkivu pod kožo nenadzorovano delijo.
Imatinib Accord is used when the patients are ‘Philadelphia chromosome positive’ (Ph+).
Zdravilo Imatinib Accord se uporablja pri bolnikih s prisotnim kromosomom Philadelphia (Ph+).
Imatinib Actavis 100 mg film-coated tablets imatinib
Imatinib Actavis 100 mg filmsko obložene tablete imatinib
Imatinib Actavis 100 mg hard capsules imatinib
Imatinib Actavis 100 mg trde kapsule imatinib
Imatinib Actavis 400 mg film-coated tablets
Imatinib Actavis 400 mg filmsko obložene tablete
Imatinib Actavis 400 mg hard capsules imatinib
Imatinib Actavis 400 mg trde kapsule imatinib
Imatinib Actavis 50 mg hard capsules
Imatinib Actavis 50 mg trde kapsule
Imatinib Actavis 50 mg hard capsules imatinib
Imatinib Actavis 50 mg trde kapsule imatinib
Imatinib Actavis is a ‘generic medicine’.
Imatinib Actavis je „generično zdravilo“.
Imatinib Actavis is also a treatment for adults for:
Zdravilo Imatinib Actavis je tudi zdravilo za odrasle s/z:
Imatinib Actavis is also a treatment for children and adolescents with CML.
Zdravilo Imatinib Actavis je namenjeno tudi zdravljenju otrok in mladostnikov s KML.
Imatinib Actavis is an anticancer medicine that contains the active substance imatinib.
Imatinib Actavis je zdravilo proti raku, ki vsebuje imatinib.
Imatinib Actavis is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut.
Zdravilo Imatinib Actavis se zaužije peroralno z obrokom hrane in velikim kozarcem vode, da se tako zmanjša tveganje za draženje želodca in črevesja.
Imatinib Actavis is indicated for the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Zdravilo Imatinib Actavis je indicirano za zdravljenje odraslih bolnikov z neresektabilnim protuberantnim dermatofibrosarkomom (DFSP dermatofibrosarcoma protuberans) in tistih odraslih bolnikov z rekurentnim in/ali metastatskim DFSP, ki niso primerni za operacijo.
Imatinib Actavis is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Zdravilo Imatinib Actavis je indicirano za zdravljenje pediatričnih bolnikov z na novo diagnosticirano kronično mieloično levkemijo (KML), s prisotnim kromosomom Philadelphia (bcr-abl) (Ph+), pri katerih presaditev kostnega mozga kot zdravljenje prve izbire ne pride v poštev. pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi. odraslih bolnikov s Ph+ KML v blastni krizi. odraslih bolnikov z na novo diagnosticirano akutno limfoblastno levkemijo, s prisotnim kromosomom Philadelphia (Ph+ ALL) skupaj s kemoterapijo odraslih bolnikov z relapsom ali neodzivno Ph+ ALL v monoterapiji odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR – platelet derived growth factor receptor) odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFR ali z obojim
Imatinib Actavis is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Zdravilo Imatinib Actavis je indicirano za zdravljenje pediatričnih bolnikov z na novo diagnosticirano kronično mieloično levkemijo (KML), s prisotnim kromosomom Philadelphia (bcr-abl) (Ph+), pri katerih presaditev kostnega mozga kot zdravljenje prve izbire ne pride v poštev; pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi; odraslih bolnikov s Ph+ KML v blastni krizi. odraslih bolnikov z na novo diagnosticirano akutno limfoblastno levkemijo, s prisotnim kromosomom Philadelphia (Ph+ ALL) skupaj s kemoterapijo odraslih bolnikov z relapsom ali neodzivno Ph+ ALL v monoterapiji odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni ern a iz trombocitov (PDGFR – platelet derived growth factor receptor) odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFR ali z obojim
Imatinib Actavis is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Zdravilo Imatinib Actavis je indicirano za zdravljenje pediatričnih bolnikov z na novo diagnosticirano kronično mieloično levkemijo (KML), s prisotnim kromosomom Philadelphia (bcr-abl) (Ph+), pri katerih presaditev kostnega mozga kot zdravljenje prve izbire ne pride v poštev; pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi; odraslih bolnikov s Ph+ KML v blastni krizi. odraslih bolnikov z na novo diagnosticirano akutno limfoblastno levkemijo, s prisotnim kromosomom Philadelphia (Ph+ ALL) skupaj s kemoterapijo odraslih bolnikov z relapsom ali neodzivno Ph+ ALL v monoterapiji odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR – platelet derived growth factor receptor) odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFR ali z obojim
Imatinib Actavis is used in combination with other anticancer medicines in adults who have been newly diagnosed with Ph+ ALL.
Zdravilo Imatinib Actavis se uporablja v kombinaciji z drugimi zdravili proti raku pri odraslih, pri katerih je bila na novo ugotovljena akutna limfoblastna levkemija s prisotnim kromosomom Philadelphia (Ph+ ALL).
Imatinib Actavis is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body.
Zdravilo Imatinib Actavis se uporablja za zdravljenje odraslih z DFSP, ki ga ni mogoče kirurško odstraniti, in odraslih, ki niso primerni za operacijo, če se je rak po zdravljenju ponovil ali razširil v druge dele telesa.
Imatinib Actavis is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα; dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Zdravilo Imatinib Actavis se uporablja za zdravljenje odraslih s HES ali KEL, ki imajo specifično prerazporeditev dveh genov, imenovanih FIP1L1 in PDGFRα; protuberantnega dermatofibrosarkoma (DFSP), tj. vrste raka (sarkoma), pri katerem se celice v tkivu pod kožo nenadzorovano delijo.